000			02096nam a22001337a 4500
008			250228b |||||||| |||| 00| 0 eng d
100			_aLayla Albaqshi
245			_aFormulation and Optimization of Aripiprazole-Loaded Nanostructured Lipid Carriers for Nose-to-Brain Delivery
300			_ap579-588
520			_aBackground: Low bioavailability, highly variable blood levels and poor clinical efficacy of Aripiprazole (ARP) are primarily linked to its hydrophobic nature. This investigation focused on the formulation of ARP loaded Nanostructured Lipid Carriers (NLCs) incorporated in thermoreversible in situ intranasal gel for brain delivery. Materials and Methods: The high-speed homogenization method was used to formulate ARP loaded NLCs. A factorial design was utilized to optimize the particle size, entrapment efficiency and drug release of NLCs by selecting Tween 80 as a surfactant and stearic acid and castor oil as solid and liquid lipids, respectively. The ARP loaded NLCs thermoreversible in situ gel was fabricated using Poloxamer 407 as a phase transition agent and carbopol 940 as a mucoadhesive agent. The gel formulation was characterized for various pharmaceutical properties and nasal ciliotoxicity. Results: The optimized NLC (Z7) had nano size (~150 nm), good entrapment efficiency (~93%) and higher drug release (~75% in 12 hr). The formulated thermoreversible in situ gel (Z2 G) showed ideal gelling temperature, gel strength, and pH suitable for nasal use in addition to steady drug release and greater permeation. The toxicity study data revealed that the gel is safe for intranasal application. Conclusion: The prepared thermoreversible in situ gel of ARP loaded NLCs showed excellent potential for intranasal use and can be a feasible alternative to oral therapy in schizophrenia.
654			_aSchizophrenia, _aAripiprazole, _a Optimization, _aPoloxamer, _aThermoreversible gel, _aIntranasal.
773	0		_0125266 _9109790 _dBanglore Association of Pharmaceutical Tearchers of India _tIndian Journal of Pharmaceutical Education and Research _x0019-5464
942			_cJA
999			_c131246 _d131246